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Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. Oxidative stress is a major cause of the gastrointestinal damage
under physical or psychological stress. Ghrelin exhibits gastropro 
tective effects and they are supposed to be derived from antioxi 
dant effects. In gastroduodenal mucosal injury, the plasma ghrelin
levels increase in response to the demand for gastroduodenal
cytoprotection. However, in the condition of Helicobacter pylori 
induced gastric mucosal severe atrophy, the plasma ghrelin con 
centration shifted to lower levels. In diabetic gastroparesis, the
regulation of ghrelin secretion is impaired with vagal nerve dys 
function. Selective ghrelin agonist is expected to represent a new
class of prokinetic agent. In addition, the plasma ghrelin levels are
also enhanced by systemic oxidative stress, and ghrelin exhibits
antioxidant effects in many organs, such as heart, pancreas, and
lung. This suggests that ghrelin would be an important player as
a sensor of systemic oxidative stress.
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Introduction The physiological response to stressor includes an increased
activity of the hypothalamic-pituitary-adrenal axis as well as
changes in gastrointestinal damage. According to Selye’s formula-
tion of the general adaptation syndrome, an increase in adrenocor-
tical activity should be related to an increase in the incidence of
gastric ulceration.(1) The strong candidate for the cause of stress
ulcer would be oxidative stress. There are some evidences that not
only physical stress, such as surgery and infection, but also psy-
chological stress leads to oxidative stress.(2,3)
Oxidative stress, which refers to a state of elevated levels of re-
active oxygen species (ROS), forms a variety of conditions that
stimulate either ROS production or a decline in antioxidant de-
fenses. Oxidative stress is involved in the pathogenesis of life-
style-related diseases, including atherosclerosis, hypertension, di-
abetes mellitus, ischemic diseases, and malignancies.(4) Several
gastrointestinal diseases, such as peptic ulcer disease and gastro-
paresis, are known to be related with the dysfunction of the anti-
oxidative properties.(5)
Ghrelin, produced and secreted by the A-like cells of the ox-
yntic glands of the stomach, stimulates growth hormone (GH) se-
cretion, gastric motility, and food intake.(6) Many researchers re-
ported the relationship between oxidative stress and the expression
or function of ghrelin.(7,8) Moreover, ghrelin administration is ex-
pected to reduce oxidative stress and control diseases.(9) Previous
studies have reported that ghrelin has an anti-inflammatory action
on the oxidative injury of the diverse organs, such as the heart,
liver and pancreas.(10–14) In the present article, we discuss the asso-
ciation of oxidative gastrointestinal damages with the potential
role of ghrelin.
Effects of Ghrelin against Gastric Mucosal Injury
Recent studies have shown that ghrelin exhibits gastroprotec-
tive effects.(15–19) Ghrelin administration reduced ethanol-induced
gastric ulceration,(15,17,18) acetic acid-induced chronic gastric and
duodenal ulceration,(16) and ischemia-reperfusion (I/R)-induced
gastric ulceration(18,19) in rats. In addition, ghrelin administration
increased mucosal cell proliferation(16) and mucosal microvascular
flow(16,18,20) in rats. These effects could be observed by intracere-
broventricular,(15,17,18) subcutaneous,(15) intraperitoneal,(18) and pe-
ripheral intravascular (19) administration of synthetic ghrelin.
The mechanism of the gastroprotective effects of ghrelin re-
mains unclear. Sibilia et al. reported that such effects of ghrelin are
mediated by endogenous nitric oxide (NO) release and requires
the integrity of sensory nerve fibers.(15) Sibilia et al.(17) also re-
ported that cyclooxygenase-1-derived prostaglandins (PGs) are
mainly involved in ghrelin-associated gastroprotection and that
NO derived from constitutive source, together with PGE2, are in-
volved in its activity. Ceranowicz et al.(16) reported that the gastro-
protective effects of ghrelin are mediated by the release of endo-
genous GH and insulin-like growth factor-1. Brzozowski et al.(18)
reported that these effects involved vagal nerve integrity, partially
depending upon afferent nerves and hyperemia mediated by
sensory neuropeptides such as calcitonin gene-related peptide
released from these nerves.
The most remarkable gastroprotective effects of ghrelin are
supposed to be derived from its antioxidant effects. Eter et al.(19)
reported that peripheral administration of ghrelin attenuated I/R-
induced gastric mucosal injury by reducing ulceration, tissue
congestion, cellular infiltration and vascular permeability in rats.
Serum level of LDH and tissue content of tumor necrosis factor α
(TNFα) were markedly reduced by the ghrelin administration. In
their study, a decrement of thiobarbituric acid reactive substance
(TBARS) and an increment in glutathione were observed, which
suggested that ghrelin has an antioxidant activity. In vitro studies,
using human polymorphonuclear cells incubated with ghrelin,
showed that ghrelin inhibited ROS generation as measured by
chemiluminecence.(19) Iseri et al.(21) reported that although alendro-
nate induces oxidative gastric damage by a local irritant effect,
ghrelin ameliorates this damage by its possible antioxidant and
anti-inflammatory powers.
Ghrelin Secretion and Gastric Mucosal Injury
The most common causes of gastric mucosal injury and peptic
ulceration are Helicobacter pylori (H. pylori) infection and the
consumption of non-steroidal anti-inflammatory drugs (NSAIDs).
H. pylori induces a strong inflammatory response, generating large
amounts of ROS during the process of colonizing the host.(20,22–29)
In the pathogenesis of NSAID-induced gastric mucosal injury,
oxygen radicals also play an important role.(30)
T
JCBN Journal of Clinical Biochemistry and Nutrition 0912-0009 1880-5086 the Society for Free Radical Research Japan Kyoto, Japan jcbn10-16GFR 10.3164/jcbn.10-16GFR Review Ghrelin and oxidative stress in gastrointestinal 
tract
Hidekazu Suzuki,* Juntaro Matsuzaki and Toshifumi Hibi
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 
35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
*To whom correspondence should be addressed.    
E mail: hsuzuki@sc.itc.keio.ac.jp J. Clin. Biochem. Nutr. | March 2011 | vol. 48 | no. 2 | 123
©2011 JCBN
H. Suzuki et al.
Although ghrelin secretion would be required to protect gastric
mucosa against ROS-induced injury, the number of the gastric
A-like cells is decreased simultaneously by gastric mucosal
injury.(31,32) Therefore, the status of ghrelin secretion in gastric
mucosal injury is complicated. The plasma total and active ghrelin
levels are known to be increased by the formation of duodenal
ulcers, which induced by administration of cysteamine, a soma-
tostatin inhibitor, in rats.(33) In a human study, enhanced plasma
ghrelin levels were observed in patients, not only with duodenal
ulcers, but also with gastric ulcers.(34) According to the report by
Isomoto et al.,(35) amomg plasma ghrelin levels of the patients with
chronic gastritis, gastric ulcer, duodenal ulcer, acute gastritis, and
normal mucosa, the levels of acute gastritis group were the
highest, and then that of chronic gastritis group were the lowest.
Within the H. pylori-positive population, the plasma ghrelin levels
of duodenal ulcer group were higher than gastric ulcer group or
chronic gastritis group.(35) The plasma total and active ghrelin
levels correlated with the serum pepsinogen I levels, as well as the
serum pepsinogen I/II ratio, and decreased with increasing extent
of gastric mucosal atrophy.(36,37) These results suggest that the
plasma ghrelin levels increase in response to the severe gastric
mucosal oxidative stress. However, in the condition of H. pylori-
induced gastric mucosal severe atrophy, the number of A like cells
as well as the plasma ghrelin concentration shifted to lower levels
with the reduction of other component cells in gastric fundic gland
due to inflammatory cell infiltrations.
Gastric Motility Dysfunction and Ghrelin
Oxidative stress induces not only gastric mucosal injury, but
also gastric motility dysfunction, such as diabetic gastroparesis.
Gastroparesis are thought to be caused by ROS-induced damage
of the networks of the interstitial cells of Cajal.(38) The authors
reported that the plasma ghrelin levels and gastric preproghrelin
mRNA expression levels are increased in rats with streptozotocin-
induced diabetes, that is known for hyperphagia.(39) In a human
study, however, the fasting plasma ghrelin level was significantly
lower in diabetes mellitus with diabetic gastroparesis than in
healthy controls.(40) The change in the plasma ghrelin levels with
sham feeding in diabetic gastroparesis patients and postsurgical
gastroparesis patients were significantly lower than in normal
subjects, although the plasma ghrelin levels increased in idio-
pathic gastroparesis.(41) Impaired regulation of the plasma ghrelin
levels in diabetic gastroparesis would be caused by vagal nerve
dysfunction.(41)
Ghrelin administration accelerated gastric emptying of a meal
in humans even in the presence of a neural dysregulation by
diabetes or surgical vagotomy.(42) Also in idiopathic gastroparesis,
administration of ghrelin enhances gastric emptying and improves
meal-related symptoms.(43) Therefore, analogues of ghrelin are
expected to represent a new class of prokinetic agents.(44) TZP-101,
the synthetic, selective ghrelin agonist, is now tested in clinical
trials. This new agent was well-tolerated in diabetes patients with
moderate-to-severe chronic gastroparesis and showed statistically
significant improvements in gastric emptying.(45,46)
Systemic Oxidative Stress and Ghrelin
Systemic oxidative stress is induced by various reasons. In
diabetes mellitus, NADPH oxidases, endothelial NO synthase
uncoupling, and protein kinase C signaling plays an important
roles for mediating increased vascular superoxide production
and endothelial dysfunction.(47) Smoking stimulates pulmonary
alveolar macrophages and increased superoxide production.(48)
During sepsis, multiple intracellular sites, such as mitochondrial,
NADPH oxidase, and Rac1 pathways, are responsible to the super-
oxide production.(49)
Several studies suggested that systemic oxidative stress enhance
the plasma ghrelin levels. The plasma ghrelin levels were corre-
lated with vascular super oxide. production and NADPH oxidase
Fig. 1. Ghrelin has antioxidant effects on systemic oxidative stress. Many kinds of systemic oxidative stress could lead to gastric mucosal injury.
Ghrelin would be released when the A like cells were damaged or repaired. Secreted ghrelin send a signal to the brain through the vagal nerve, and
enhance the antioxidant reaction in the body.doi: 10.3164/jcbn.10 16GFR
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activity in patients with atherosclerosis.(50) Plasma ghrelin was
elevated in cachectic patients with chronic heart failure, associated
with increases in GH and TNFα.(51) Smoking acutely increased the
plasma ghrelin levels.(52) On the other hand, in the early stage of
sepsis, ghrelin levels decreased, although the activity of its
receptor was markedly elevated in rats.(53) In patients with acute
pancreatitis, the plasma ghrelin levels increased after patients’
recovery, as compared with the levels before therapy.(54) Decreased
ghrelin levels in the early phase of sepsis or pancreatitis would be
caused by the damage of gastric A like cells. With repairment of
the A like cells, the plasma ghrelin levels would recover after
sepsis or pancreatitis.
Taken together, it is considered that gastric mucosa would play
an important role for sensing a systemic oxidative stress (Fig. 1).
Exposure to oxidative stress could lead to gastric mucosal injury,
and ghrelin would be released when the A like cells were damaged
or repaired. Secreted ghrelin would have an anti-inflammatory
action on the oxidative injury of the several organs, such as
increasing cardiac output,(55) vasorelaxation,(56) attenuation of acute
pancreatic damage,(57) and attenuation of acute lung injury,(58) as
well as rapid repairment of gastric epithelial cells. Ghrelin would
be also secreted from the stomach as an anti-inflammatory player
for the systemic oxidative injury.
Conclusions
Ghrelin has the possible antioxidant and anti-inflammatory
effects. Selective ghrelin agonist would be expected as a new
agent to treat not only gastrointestinal motility dysfunction, but
also gastric mucosal injury, cardiovascular disease, and various
systemic diseases induced by oxidative stress. The stomach would
be an important organ as a sensor of systemic oxidative stress.
Abbreviations
ROS reactive oxygen species
I/R ischemia-reperfusion
GH growth hormone
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